Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1
Status:
Recruiting
Trial end date:
2028-12-15
Target enrollment:
Participant gender:
Summary
A global, multi-center, Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and
Safety of Encaleret Compared to Standard of Care in Participants with Autosomal Dominant
Hypocalcemia Type 1 (ADH1)
Phase:
Phase 3
Details
Lead Sponsor:
Calcilytix Therapeutics, Inc., a BridgeBio company
Treatments:
26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin D3 Alfacalcidol Calcitriol Calcium Hydroxycholecalciferols Vitamin D